SMARCA1 and malignant peripheral nerve sheath tumor: PROTACs targeting BRD4 and BRD9, components of the SWI/SNF (BAF) remodelling complex, have also shown efficacy in preclinical MPNST, malignant rhabdoid tumour and synovial sarcoma models [220–222].